Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

BACKGROUND: Immune checkpoint blockade (ICB) targeting programmed cell death protein 1 and cytotoxic T lymphocyte-associated protein 4 has achieved modest clinical activity as salvage therapy in relapsed small cell lung cancer (SCLC). We conducted this signal-finding study to assess the efficacy of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Pakkala, Suchita, Higgins, Kristin, Chen, Zhengjia, Sica, Gabriel, Steuer, Conor, Zhang, Chao, Zhang, Guojing, Wang, Shuhua, Hossain, Mohammad S, Nazha, Bassel, Beardslee, Tyler, Khuri, Fadlo R, Curran, Walter, Lonial, Sagar, Waller, Edmund K, Ramalingam, Suresh, Owonikoko, Taofeek K
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7754662/
https://ncbi.nlm.nih.gov/pubmed/33428583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001302
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados